Back to Results
First PageMeta Content
Fundamental analysis / Financial ratios / Business / Valuation / EV/EBITDA / Earnings before interest / taxes / depreciation and amortization / Sun Pharmaceutical / Income / P/E ratio / Finance / Generally Accepted Accounting Principles / Accountancy


SUNPMOSL-RU-8PG.p65
Add to Reading List

Document Date: 2012-02-16 00:51:48

Open Document

File Size: 211,78 KB

Share Result on Facebook

Company

Marco Polo Securities Inc. / Sun Pharmaceuticals Sun Pharmaceuticals / Emerging / Taro / Caraco Pharma / CVS / S&P / Bloomberg / Sun Pharmaceuticals Proposes / Sun Pharmaceuticals / Motilal Oswal Securities Limited / Sun Pharma / /

Country

Japan / United States / United Kingdom / India / /

Currency

Rs / USD / /

/

Event

FDA Phase / M&A / Funding / Earnings Guidance / Reorganization / /

Facility

Para-IV pipeline / /

/

IndustryTerm

contract manufacturing revenues / select products / restricted bank deposits / manufacturing facilities / certain key products / /

Organization

U.S. Securities and Exchange Commission / FINRA / FDA / NASD / /

Person

Taro / Nimish Desai / /

/

Position

independent financial advisor / research analyst / Major Institutional Investors / registered broker-dealer in the United States / No No No No Analyst / going forward / growth driver / Analyst / /

Product

USFDA / /

Technology

API / CMP / /

SocialTag